South San Francisco-based clinical-stage biopharmaceutical firm Catalyst Biosciences, Inc. is ramping up its efforts to develop and market innovative treatments targeting liver fibrosis associated with various chronic liver diseases, both in the US and overseas. One of its primary products in the pipeline is Hydronidone, which has already completed phase 1 clinical testing for the treatment of nonalcoholic steatohepatitis - a severe variant of nonalcoholic fatty liver disease. Catalyst Biosciences was founded in 2002, and continues to push the boundaries of advanced drug development in the field of liver health.
Catalyst Biosciences, Inc.'s ticker is CBIO
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 11-50 employees working at Catalyst Biosciences, Inc.
It is https://www.catalystbiosciences.com/
Catalyst Biosciences, Inc. is in the Healthcare sector
Catalyst Biosciences, Inc. is in the Biotechnology industry
The following five companies are Catalyst Biosciences, Inc.'s industry peers: